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Abstract 
RING-in-between-RING (RBR) Ubiquitin (Ub) ligases are a distinct class of E3s, defined by a 
RING1 domain that binds E2 Ub-conjugating enzyme and a RING2 domain that contains an 
active-site cysteine similar to HECT-type E3s. Proposed to function as RING-HECT-hybrids, 
details regarding the Ub transfer mechanism used by RBRs have yet to be defined. When paired 
with RING-type E3s, E2s perform the final step of Ub ligation to a substrate. In contrast, when 
paired with RBR E3s, E2s must transfer Ub onto the E3 to generate a E3~Ub intermediate. We 
show that RBRs utilize two strategies to ensure transfer of Ub from the E2 onto the E3 active 
site. First, RING1 domains of HHARI and RNF144 promote open E2~Ubs. Second, we identify 
a Ub-binding site on HHARI RING2 important for recruitment of RING1-bound E2~Ub. 
Mutations that ablate Ub binding to HHARI RING2 also decrease RBR ligase activity, consistent 
with RING2 recruitment being a critical step for the RBR Ub transfer mechanism. Finally, we 
demonstrate that the mechanism defined here is utilized by a variety of RBRs. 
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Introduction 
Ubiquitin (Ub) is a small protein involved in the regulation of a wide variety of cellular 
processes. Ub signaling occurs through the covalent attachment of the Ub C-terminus to protein 
substrates via a trio of enzymes: a Ub-activating enzyme (E1), a Ub-conjugating enzyme (E2), 
and a Ub ligase (E3). E1s activate the C-terminus of Ub in an ATP-dependent manner and 
facilitate the transfer of Ub onto the E2 active site cysteine (Cys) via transthiolation to generate 
an E2~Ub conjugate (“~” denotes a thioester bond). Most E2~Ub conjugates can pair with one or 
more E3 Ub ligases to facilitate Ub transfer onto a substrate amino group, usually the sidechain 
of a lysine (Lys). There are three major types of eukaryotic E3 Ub ligases: Really Interesting 
New Gene (RING)-type E3s (including Ubox E3s), Homologous to E6AP C-Terminus (HECT)-
type E3s, and RING-in-between-RING (RBR) E3s.  
A majority of E3s are RING-type ligases that use a conserved RING/Ubox-domain defined by a 
characteristic cross-brace fold to bind the E2~Ub. These E3s bind both the substrate and E2~Ub 
to facilitate Ub transfer from the E2~Ub directly onto a substrate amino group, usually a lysine 
sidechain. In addition to this scaffolding role, RING-type E3s activate the E2~Ub to transfer Ub 
onto Lys residues (an aminolysis reaction) by promoting closed conformations of the E2~Ub [1-
5]. A crucial feature of the RING-type activation mechanism is a conserved basic residue 
(Lys/Arg) that contacts both the E2 and the Ub, referred to as the “linchpin” residue [1]. HECT-
type E3s bind the E2~Ub via a conserved HECT domain that is structurally distinct from a RING 
domain. Importantly, HECT-type E3 ligases contain a conserved Cys residue on which an 
obligatory E3~Ub intermediate is formed prior to Ub transfer onto a substrate Lys. This 
mechanism requires two types of chemical reactions: 1) a transthiolation reaction transfers Ub 
from E2~Ub to the E3 active site Cys to generate a reactive E3~Ub species and 2) a subsequent 
aminolysis reaction transfers the C-terminus of Ub from the E3 to a substrate Lys to form a 
stable isopeptide bond. Unlike the mechanism utilized by RING-type E3 ligases that induce 
closed E2~Ub conformations, available data on HECT ligases suggest that they do not need a 
closed E2~Ub for activity [6, 7]. 
The third class of E3 ligases was discovered more recently when two RBR E3s, HHARI (human 
homologue of Ariadne) and Parkin, were shown to function via a RING/HECT-hybrid 
mechanism [6]. Despite containing an eponymous E2-binding RING domain, RBR E3s proceed 
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through an E3~Ub thioester intermediate similar to HECT-type E3s.  The functional importance 
of an active site Cys for catalytic activity has since been confirmed for other RBR E3 ligases 
including HOIP, HOIL-1L, TRIAD1, and RNF144 [8-11]. Although a small class with only 12-
14 members in the human genome, RBR E3s are involved in many essential cellular pathways. 
The most studied RBR E3 is Parkin for which mutations have been linked to autosomal-recessive 
juvenile Parkinson’s disease [12, 13]. HOIP and HOIL-1L are distinctive for their unique ability 
to generate linear Ub chains that are crucial regulators of the NF-κB signaling pathway [14-17]. 
HHARI and TRIAD1 belong to the Ariadne family of RBR E3 ligases defined by their C-
terminal auto-inhibitory Ariadne domain. HHARI and its homologues in Drosophila and C. 
elegans have been implicated in processes including regulation of translation via the translation 
initiation factor 4EHP, cellular proliferation, and development [18-21]. 
RBR E3s are defined by three characteristic domains each of which coordinates two Zn2+ ions: 
RING1, in-between RING (IBR), and RING2. An RBR unit may be found at any position 
relative to other domains within an RBR E3, but its subdomains RING1-IBR-RING2 always 
appear in order (N-term to C-term). RING1 is the E2-binding domain and RING2 contains the 
active site Cys that when mutated to an Alanine (Ala) renders RBRs inactive [6, 8-11, 22, 23]. 
While RING1 domains adopt structures similar to canonical RING-type E3 ligases, RING2 
domains do not resemble canonical RING domains, either structurally or functionally. The IBR 
domain adopts a structure that is similar to that of RING2, though its function remains elusive.  
As mentioned above, canonical RING-type E3s activate an E2~Ub conjugate by promoting 
closed E2~Ub conformations that exhibit increased reactivity towards the amino groups of Lys 
residues.  A signature of closed conformations are non-covalent interactions between a surface 
on the E2 formed by the “cross-over” helix (also known as helix-2) and the hydrophobic patch or 
“I44 surface” of Ub. Mutations of residues within the E2:Ub interface abrogate activation by 
RING-type E3 ligases [1-5]. Paradoxically, HHARI RING1 fails to activate the E2~Ub for Ub 
transfer by aminolysis despite their close structural resemblance to canonical RING domains [6]. 
Furthermore, mutations of the E2 cross-over helix that significantly decrease in vitro Ub transfer 
activity with canonical RING-type E3s do not affect Ub transfer activity of the RBR E3 HHARI 
[1]. These observations imply that HHARI RING1 is mechanistically distinct from its canonical 
RING relatives in ways yet to be defined.  
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RBR E3s such as Parkin, HOIP, and HHARI display activity with a variety of E2s; in particular 
they are all active with two well characterized human E2s, UbcH5 and UbcH7 [6, 8, 9]. While 
most E2s, including UbcH5, are able to perform both transthiolation reactions and aminolysis 
reactions, UbcH7 solely performs transthiolation reactions [6]. This suggests that UbcH7 can 
function with HECT-type and RBR-type E3s, but not with RING-type E3s. Notably, C.elegans 
orthologues of HHARI and UbcH7 act together in pharyngeal development, suggesting that 
UbcH7 is a biologically relevant E2 for HHARI [20, 24]. But HHARI, Parkin, and HOIP are also 
known to work with E2s that are able to transfer Ub directly to (Lys) amino groups. Importantly, 
HOIP specifically generates linear Ub chains regardless of the chain linkage preference of the E2 
with which it works [6, 8, 9, 15, 25-28]. This suggests a dichotomy in the determining factor for 
product formation: in the case of RING-type E3s, the identity of the E2 determines the type of 
product while in RBR E3s, the E3 determines the type of product. This leads to the question: 
How do RBR E3s ensure that transfer of Ub occurs via the E3 active cite Cys to maintain control 
of product formation? 
Here we report the mechanistic strategies used by RBR-type E3s to transfer ubiquitin from the 
E2 onto the E3. First, we show that RING1 domains of HHARI and RNF144 specifically inhibit 
closed E2~Ub conformations. This strategy ensures that Ub transfer occurs via the RBR active 
site by preventing off-target Ub transfer events. Second, we identify a weak but functionally 
important interaction between HHARI RING2 and Ub which serves to recruit RING2 to the 
RING1:E2~Ub complex. In structures of auto-inhibited RBR E3s, RING1 and RING2 are far 
from each other and a large domain rearrangement is required to bring the RING2 active site 
close to the E2~Ub active site bound to RING1 [29-34]. Consistent with this notion, mutations in 
either Ub or RING2 at the Ub:RING2 interface substantially reduce Ub transfer from E2~Ub to 
RING2. Finally, we demonstrate that the mechanism defined here is utilized by a variety of RBR 
E3 ligases, indicating its generality for this important class of enzymes.  
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Results 
RBR E3 ligases do not require closed states of E2~Ub for ubiquitin transfer 
In the absence of an E3, UbcH5~Ub is highly dynamic, with the Ub moiety populating mainly 
open states relative to the E2 [35]. Upon binding a canonical RING/Ubox, UbcH5~Ub is biased 
towards closed states that are activated for aminolysis reactions which constitute the final step in 
Ub transfer by RING-type E3s. Closed E2~Ub states bound to RING/Ubox domains have been 
visualized in several co-crystal structures and by NMR [1-4]. Mutation of a residue on the cross-
over helix of UbcH5 (L104Q) disrupts formation of closed states and dramatically decreases 
ubiquitination activity with canonical RINGs such as BRCA1/BARD1 (Fig 1A) [1]. Though 
RBRs contain an E2-binding RING domain (RING1), UbcH5L104Q shows robust activity with 
HHARIRBR, TRIAD1ΔAri, ParkinRBR, and HOIPRBR-LDD (Fig 1A & EV1; information regarding 
constructs used in this study is included in Appendix Table S1). This observation indicates that 
RBR E3s do not require closed E2~Ub conformations for Ub transfer activity. Therefore, we 
wondered whether RING1s of RBRs are able to induce closed E2~Ub conformations. To address 
this question, we used an active site Cys-to-Ser E2 mutant to generate a stable oxyester mimic of 
E2~Ub (“E2-O-Ub”). In a previous study, the NMR spectrum of 15N-UbcH5c-O-15N -Ub 
exhibited chemical shift perturbations (CSPs) in the presence of a canonical RING/Ubox that are 
hallmarks of the closed state [1]. We therefore performed similar NMR binding experiments of 
15N-UbcH5c-O-15N -Ub with the HHARI RING1 domain (residues 177-270).  Comparable to 
previous observations for canonical RINGs, binding of HHARI RING1 to UbcH5-O-Ub occurs 
in fast-to-intermediate exchange (peaks shift and broaden), indicating that the interaction is of 
fairly modest affinity (Fig 1B). CSP analysis of free UbcH5-O-Ub compared to HHARI RING1-
bound UbcH5-O-Ub revealed residues that are perturbed upon HHARI RING1 binding: these 
define a surface composed of residues in helix 1, loops 4, and 7 – those known to be central to 
binding of UbcH5 by canonical RING-type E3s [2, 3, 36-38]. These results indicate that HHARI 
RING1 binds UbcH5 in a manner similar to that used by canonical RINGs (Fig 1C). However, 
CSPs are not observed for most residues of the UbcH5 cross-over helix nor are they are observed 
for the Ub moiety upon HHARI RING1 binding to UbcH5-O-Ub (Fig 1C). Together, these 
observations are strong evidence that HHARI RING1 does not promote UbcH5-O-Ub closed 
conformations. This finding provides a basis for understanding two previous observations: 1) 
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HHARI RING1 does not enhance UbcH5~Ub reactivity towards free Lys [6] and 2) HHARIRBR 
exhibits robust activity with the cross-over helix mutant UbcH5L104Q ([1] and Fig 1A). 
A highly conserved position in canonical RINGs, called the linchpin residue, is largely 
responsible for the ability to promote closed E2~Ubs by forming hydrogen bonds to both E2 and 
Ub [1-4]. In RINGs, the linchpin is most often a basic residue (Arg or Lys) and is occasionally a 
neutral H-bonding residues such as Asn. HHARI contains an Asp residue in the structurally 
analogous position to the linchpin, and RBRs in general do not share a common residue that 
could fulfill the function of a hydrogen-bonding linchpin (Fig 1D). This provides one possible 
explanation for HHARI RING1’s failure to induce closed states of UbcH5~Ub.  
HHARI RING1 promotes open E2~Ub conformations  
UbcH7 is a specialized E2 that can only perform transthiolation reactions, making it an 
RBR/HECT-specific E2 [6]. UbcH7 is active in vitro with many, if not all, RBR-type E3 ligases. 
Notably, C.elegans orthologs of UbcH7 and HHARI are vital partners in vivo [20] prompting us 
to examine the effects of HHARI RING1 binding on UbcH7~Ub.  
Unexpectedly, we discovered that in the absence of an E3, UbcH7-O-Ub populates closed 
conformations to a considerable extent. NMR CSP analysis of UbcH7-O-Ub compared to free 
UbcH7 reveals perturbed residues in the cross-over helix of UbcH7 in addition to residues 
around the active site (Fig 2A). The perturbations identify a surface similar to that seen in closed 
states of other E2~Ubs [1-4, 35]. To verify this conclusion, we conjugated I44A-Ub to 15N-
UbcH7 because UbI44A disrupts closed states of other E2~Ubs [1-3]. Indeed, residues of the 
UbcH7 cross-over helix as exemplified by Q106 and S107 resonate at positions more similar to 
free UbcH7 than to UbcH7-O-Ub when I44A-Ub is the conjugated species (Fig 2B & Appendix 
Fig S1). Altogether, these data are consistent with UbcH7~Ub adopting closed conformations in 
the absence of an E3 that require surfaces that include the cross-over helix of UbcH7 and the 
I44-surface of Ub (Fig 2A&B and Appendix Fig S1).  
We next asked what effect HHARI RING1 binding has on UbcH7~Ub. Due to the high affinity 
of UbcH7 for HHARI RING1 [29], residues affected by complex formation exhibit slow-
exchange behavior in 1H-15N-HSQC-type NMR experiments. This property leads to peak 
intensity loss rather than peak shifting in binding experiments (Fig EV2A). First, the effect of 
8 
 
HHARI RING1 binding to unconjugated UbcH7 was analyzed to map the RING1 binding 
surface. Comparison of peak intensities between the spectrum of free 15N-UbcH7 and of RING1-
bound 15N-UbcH7 reveals that the RING1-binding surface on UbcH7 is very similar to that 
mapped for UbcH5 bound to RING1 (Fig EV2B&C). To simplify analysis of the UbcH7-O-Ub 
conjugate, either 15N-labeled UbcH7 or 15N-labeled Ub was incorporated into conjugates for 
HHARI RING1 binding experiments. Turning to the Ub moiety, an overlay of NMR spectra of 
free UbcH7-O-15N-Ub and RING1-bound UbcH7-O-15N-Ub shows several perturbed Ub 
resonances, as exemplified in Fig 3A. Notably, a majority of Ub residues (47, 49, 71-74) that are 
affected by HHARI RING1 binding to UbcH7~Ub are among those identified in a comparison of 
UbcH7~Ub versus free Ub (Appendix Fig S2). For example, when UbcH7~Ub binds to RING1, 
the Ub Q49 resonance, which experiences the largest chemical shift upon Ub conjugation to 
UbcH7, moves back close to its position in the spectrum of free Ub (Fig 3A & Appendix Fig S2). 
The simplest explanation for this observation is that RING1 binding alters or disrupts contacts 
between Ub and UbcH7 in UbcH7~Ub.  Importantly, chemical shifts for Ub residues within both 
RING1-bound UbcH7~Ub and UbcH5~Ub (Fig 1B&3A and Appendix Fig S2) are similar to 
those seen for free Ub. We propose that RING1 promotes open conformations of E2~Ub. We 
note that while Ub resonances of RING1-bound UbcH7~Ub are similar to those of free Ub, they 
are not identical, indicating that the environment of the Ub moiety may be affected by its 
proximity to RING1 in the complex (Fig 3A & Appendix Fig S2).  
For additional evidence of disruption of UbcH7~Ub closed conformations by RING1 binding, 
we used 1H-13C-HSQC type experiments and published assignments to observe and interpret 
sidechain resonances of 13C-UbcH7 [39]. Sidechain resonances of UbcH7 cross-over helix 
residues shift upon conjugation to Ub, consistent with closed UbcH7~Ub states (as exemplified 
in Fig 3B and Appendix Fig S3). Figure 3B compares three spectra: free 13C-UbcH7 (blue) and 
13C-UbcH7-O-Ub in the absence (black) and presence of HHARI RING1 (red). Notably, the 
methyl resonance of the surface-accessible cross-over helix residue Ala110 is significantly 
perturbed upon conjugation of Ub to UbcH7, as evidenced by the lack of a (black) peak on or 
near the blue peak labeled Ala110 (Fig 3B), indicating that the side chain of Ala110 interacts 
with Ub. Upon the addition of RING1 (red spectrum), the Ala110-CH3 peak reappears at the 
chemical shift observed for Ala110-CH3 in free 13C-UbcH7 (blue), evidenced by the red peak 
that overlays the blue Ala110 peak (Fig3B & Appendix Fig S3). These data corroborate the 
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notion that UbcH7~Ub populates closed conformations in the absence of an E3 and that these are 
disrupted by HHARI RING1 binding.   
To test whether disruption of UbcH7~Ub closed state is specific to HHARI RING1, we assessed 
the effects of binding of other RING domains to UbcH7-O-15N-Ub. Though all domains tested 
bind to UbcH7, neither the canonical RING heterodimer BRCA1/BARD1 nor the UBox E4BU 
disrupted the closed conformation of UbcH7~Ub while RNF144 RING1 produced effects similar 
to HHARI RING1 upon binding to UbcH7-O-15N-Ub (Fig 3C & Appendix Fig S4). Thus, RBR-
type RING1 domains share the ability to discourage closed UbcH7~Ub conformations, making 
them functionally distinct from canonical RING-type domains despite their structural 
similarities. Finally, we wondered whether HHARI RING1 can disrupt closed conformations of 
other E2~Ub species. Ubc13~Ub detectably populates closed conformations in the absence of E3 
[35].  Indeed, addition of HHARI RING1 to Ubc13-O-15N-Ub leads to chemical shifts of Ub 
resonances back towards their positions in free Ub, along the same trajectory as the “open” to 
“closed” perturbations (Fig EV3). Thus, the ability of HHARI RING1 to disrupt closed E2~Ub 
states is not limited to UbcH7.  
Closed E2~Ubs are associated with increased reactivity towards Lys amino groups [1, 2, 3 , 4-
6].Therefore a possible corollary to increased open E2~Ub conformations is an increase in 
transthiolation (reactivity towards Cys) as this is the relevant nucleophile in the context of RBR-
type E3 ligases. However, we did not observe a difference between UbcH7~Ub reactivity 
towards free Cys in the absence versus presence of HHARI RING1 (Appendix Fig S5).  
Based on these data, we propose a mechanism in which not only does the RING1 of an RBR fail 
to promote closed E2~Ub states, it actively discriminates against them.  
RING1 opening of E2~Ub enforces Ub transfer via the RING2 active site Cys 
RBR E3s are active with E2s that are also active with canonical RING-type E3s [6, 8, 9, 15, 25-
28]. This implies that the E2~Ub must distinguish between its two reaction modes 
(transthiolation and aminolysis) based on the type of E3 ligase with which it interacts. Open 
E2~Ub states are minimally reactive towards Lys and require activation for canonical RING-type 
Ub transfer [1-4]. We wondered whether there would be negative consequences if an RBR 
RING1 could also stabilize closed, aminolysis-activated E2~Ubs as seen with canonical RINGs. 
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However, our efforts to generate a HHARI RING1 that activates the E2~Ub for aminolysis by 
mutating positions known to be critical in canonical RING domains failed. We took an 
alternative approach to assess the consequence of having aminolysis activity in the context of an 
RBR E3 by replacing the RING1 domain within the HHARI RING1-IBR-RING2 (WT-RBR-
domain) construct with the Ubox domain of E4BU to generate a Ubox-IBR-RING2 (UBR) 
hybrid (Fig 4A). Ubox domains are E2-binding domains that contain RING-like folds, but do not 
ligate Zn2+ and are therefore more likely to fold successfully within a hybrid construct. 
Importantly, the Ubox domain of E4BU has been shown to activate UbcH5~Ub for aminolysis 
via promotion of closed E2~Ub conformations [1].  
We posited that an RBR with the ability to activate E2~Ub for aminolysis might circumvent the 
obligate transthiolation reaction through the active site Cys residue in RING2. In in vitro auto-
ubiquitination assays where the RBR E3 acts as a proxy substrate, Ub transfer occurs through the 
active site Cys as the active site mutation C357A essentially abrogates ubiquitination activity of 
HHARIRBR (Fig 4B, LEFT panel). Remarkably, this is not the case for reactions carried out by 
the UBR-hybrid as the active-site-dead (C357A) version retains substantial auto-ubiquitination 
activity (Fig 4B, RIGHT panel). The result implies that UbcH5~Ub transfers its Ub directly to 
Lys residues when bound to the hybrid E3 construct as it does not require the active site Cys. 
Our UBR-hybrid construct demonstrates that the presence of an E2-binding domain that can 
activate E2~Ub for aminolysis creates an RBR that no longer undergoes obligate transfer to and 
through the active site Cys on RING2. Altogether we conclude that by favoring open E2~Ub 
conformations, HHARI RING1 (and likely other RING1 domains) prevents off-target 
ubiquitination events catalyzed by the E2~Ub and consequently enforces Ub transfer through the 
RING2 active site Cys.  
The hydrophobic surface of Ub is required for transfer of Ub to the RBR active site. 
Mechanistically speaking, there is no need for RBR E3s to enhance E2~Ub ability to transfer Ub 
through aminolysis. Furthermore, as we demonstrated above, induction of closed E2~Ub can 
lead to undesirable off-target Ub transfer (Fig 4). These two rationales may be sufficient to 
explain why RBR E3s prefer to keep E2~Ubs in open states. However, we noted that the 
hydrophobic (“I44”) surface of Ub that plays a critical role in protein-protein interactions is 
sequestered in closed E2~Ub but is exposed in open states. Furthermore, mutations of the Ub 
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hydrophobic patch have previously been shown to decrease auto-ubiquitination activity in Parkin 
[40]. This raises the question whether the exposed Ub surface has a specific role in Ub transfer 
by RBR E3s.  In in vitro ubiquitination assays with the RBR E3s HHARIRBR, ParkinRBR, and 
HOIPRBR-LDD, use of Ub species that carry a mutation in a single hydrophobic patch residue led 
to reduced activity (Fig 5A&B, Fig EV4A). These results indicate that the Ub hydrophobic patch 
is required for Ub transfer by RBRs..   
Current models of RBR-type mechanisms assume a two-step process for Ub transfer: first, Ub is 
transferred from the E2~Ub to the active site Cys on RING2 to form an E3~Ub, and second, Ub 
is transferred from the E3~Ub to a substrate amino group. In the case of HOIPRBR-LDD, it has been 
shown that the I44-surface is not required for binding of the acceptor Ub [9]. We therefore 
postulated that the I44-surface might be required for the first step of the RBR Ub transfer 
mechanism. To test this hypothesis, we compared discharge rates for E2~Ub charged with either 
wt-Ub or mutant Ub prior to incubation with ParkinRBR. In this assay, the disappearance of 
E2~Ub can be observed directly by SDS-PAGE (in the absence of reducing agent). 
UbcH7~UbWT disappears rapidly when incubated with Parkin, whereas the UbcH7~UbI44A is 
stable in the presence of Parkin indicating that Ub transfer from the E2~Ub to Parkin RING2 is 
impaired when the Ub to be transferred is I44A-Ub (Fig 5C). Because E3~Ub intermediates for 
RBR E3s are often short-lived and therefore difficult to detect, it is not possible to say whether 
the observed disappearance of the E2~Ub is via transfer to the Parkin RING2 active site Cys or 
merely hydrolysis. To address this question, we took advantage of RING2 mutations in HOIP 
and HHARI (H887A and H359A respectively) that stabilize the E3~Ub [29, 41]. In assays with 
HOIPH887A or HHARIH359A as the E3, both the UbcH7~Ub and the E3~Ub conjugates are 
detected. Single mutations in the Ub hydrophobic surface show both reduced disappearance of 
the E2~Ub (similar to Parkin) and, importantly, decreased generation of E3~Ub (Fig 5D&E and 
Fig EV4B). These experiments provide strong evidence that the hydrophobic patch of Ub plays a 
key role in the first step of the RBR mechanism, namely for Ub transfer from the RING1-bound 
E2 to the Cys on RING2. Whether the Ub hydrophobic patch is also required for the second step 
of Ub transfer by RBR E3s remains to be addressed in future studies.  
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HHARI RING2 binds to the hydrophobic patch of Ub 
A possible explanation for the observation that the hydrophobic patch of Ub is required for 
transfer of Ub from the E2 onto the E3 active site is that the Ub surface binds to the RING2 
domain to recruit its active site to the E2~Ub. Consistent with this notion, some RBR RING2 
domains retain weak but detectable Ub transfer activity independent of RING1, suggesting that 
when protein concentrations are high enough in vitro, RING2 can recruit an E2~Ub on its own 
[9, 41-44]. We reasoned that an interaction between free Ub and RING2 is likely to be of very 
low affinity. Because Ub is extremely soluble, we performed NMR binding experiments using 
100 μM 15N-HHARI RING2 (residues 325-396) and high concentrations of Ub (1 mM; Fig 6A). 
A subset of resonances disappear or shift in the presence of WT-Ub but not of V70A-Ub, the Ub 
mutant that most affects HHARI activity (Fig 5A and Fig 6A top versus middle panels). The 
result has two implications: 1) the effects observed with WT-Ub are not merely due to the very 
high Ub concentrations used and 2) there is a direct, albeit low affinity interaction between 
RING2 and the hydrophobic surface of Ub. An NMR solution structure of HHARI RING2 has 
been solved and therefore the NMR spectrum is assigned [45], allowing perturbed residues to be 
identified and mapped onto the RING2 domain structure. The resulting surface forms a 
contiguous patch in proximity to the active site Cys357 and extends into the linker between IBR 
and RING2 (Fig 6B). We were surprised to see involvement of the linker which is not observed 
in the crystal structure [29 ] so we repeated the binding experiment using a RING2 construct that 
lacks most of the RING2-IBR linker (HHARI RING2-ΔL, residues 336-395).  Remarkably, 
binding of Ub to 15N-HHARI RING2-ΔL is substantially reduced, consistent with the linker 
serving as part of the binding interface (Fig 6A, bottom panel).  
Mutations in HHARI residues most highly perturbed by Ub binding were tested for functional 
consequences in auto-ubiquitination assays. In the context of HHARIRBR, Trp336, Glu352, and 
Arg363 were each mutated to Ala, and Thr341 was changed to an Asn to mimic the pathogenic 
mutation T415N in the analogous conserved residue in Parkin (Fig 6C). Strikingly, T341N 
decreases HHARI’s ligase activity substantially and both W336A and E352A show a moderate 
reduction of ubiquitination activity while R363A has no observable effect (Fig 6D). NMR 
binding experiments confirm that the mutations that decrease ligase activity also decrease Ub 
binding to HHARI RING2 (Fig 6E). Together the results corroborate that RING2 and linker 
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residues are important both for Ub binding and HHARI activity, leading us to propose that the 
hydrophobic surface on the donor Ub binds and recruits RING2 and that this step is crucial for 
overall RBR activity. 
 
Discussion 
Until a few years ago, RBR E3 ligases were considered to be RING-type E3 ligases because they 
were thought to contain two RING domains based on primary sequence analysis. Today we 
know that only RING1 domains adopt a fold similar to canonical RING domains whereas 
RING2 domains fold into a different domain architecture that is shared by IBR domains [29-32, 
41, 43, 46]. In common with canonical RING domains, RING1 binds an E2~Ub, but RING2 
contains an active site Cys, similar to HECT-type E3 ligases, leading to the proposal that RBR 
E3 ligases act via a RING-HECT-hybrid mechanism [6] (Fig 7A). We sought here to define the 
mechanistic details of the RBR E3 HHARI and in so doing have discovered unique strategies 
that are shared among RBR E3s. Previously reported results had hinted that RBR E3s differ in 
essential functional ways from their eponymous RING-type E3 cousins, despite the structural 
similarity of RING1 domains and canonical RING domains. For example, HHARI retains the 
ability to transfer Ub using the UbcH5L104Q mutant that abrogates Ub transfer activity with 
canonical RING-type E3 ligases [1]. Also, HHARI RING1 does not increase the Lys reactivity 
of UbcH5~Ub [6]. Together, these results suggested that HHARI RING1 does not function like a 
canonical RING domain. Here we demonstrate that RING1 domains not only fail to induce 
closed E2~Ub conformations – a mechanistic hallmark of canonical RING-type E3 ligases—but 
instead RING1s actively favor open E2~Ub conformations. This strategy ensures that the 
transfer of Ub proceeds via the active site Cys on RING2 and therefore that the type of product 
generated (e.g., mono- or a specific poly-Ub chain) is determined by the RBR E3 and not by the 
E2  (Fig 7B).  
We propose that the disfavoring of closed E2~Ub states by RING1 is a common mechanistic 
feature of RBR E3s for several reasons. First, we demonstrate by NMR that the RING1 domain 
from another RBR, RNF144 also promotes open UbcH7~Ub states (Fig 3C). Second, the RBR 
E3s HHARI, Parkin, TRIAD1, and HOIP all exhibit robust Ub transfer activity with UbcH5L104Q 
14 
 
in vitro (Fig 1A & EV1). Third, not promoting closed E2~Ub states is functionally important as 
it prevents off-target ubiquitination events catalyzed by the E2~Ub (Fig 4). In sum, RING1 
domains act in an opposite manner to canonical RINGs in that they actively inhibit E2~Ub 
closed states and consequently, suppress E2~Ub aminolysis reactivity and therefore E2 
specificity. Such a strategy can be rationalized in the context of the overall RBR mechanism in 
which an E2~Ub must transfer Ub specifically onto a Cys (the active site of RING2) and not to a 
Lys residue. RBR E3 ligases are rendered catalytically inactive when their active site Cys is 
mutated to an Ala proving that the Ub transfer occurs through an obligate covalent E3~Ub 
conjugate [6, 8-11, 22, 23]. Therefore, Ub transfer from the E2~Ub to Lys residues on either the 
E3 itself or another protein in its vicinity would be off-target and likely detrimental to the 
cellular processes that RBR E3s regulate. This unique feature of RBR RING1 domains allows 
RBR E3s to accept Ub from a variety of E2~Ubs including E2s that are able to transfer Ub onto 
either Lys or Cys, while ensuring that Ub transfer occurs through the active site Cys on RING2. 
Such discrimination is crucial, as in all cases known to date, it is the enzyme that carries out the 
final aminolysis reaction that determines the type of Ub modification on a given substrate. In the 
case of RING-type E3s it is the E2 that determines whether poly-Ub chains are built as well as 
the chain topology (for example K48- vs. K63-linked Ub chains). But in the case of E3 ligases 
that utilize an E3~Ub intermediate, the E3 controls the final Ub product formation. For example, 
the E2 E2-25K possesses intrinsic ability to build K48-linked Ub chains in the absence of an E3, 
but this preference is suppressed when paired with the linear chain building complex that 
contains HOIL-1L/HOIP known to build linear Ub chains [15]. In such reactions the E2~Ub acts 
as a supplier of Ub for the E3, but must not modify substrates directly. Altogether, these 
properties enable use of the same E2s by both RING-type and RBR E3s to follow the adage “The 
last guy holding the activated Ub/Ubl gets to determine the product” [47]. 
Consistent with this general principle, the only available structure of a HECT/E2~Ub complex 
shows the E2~Ub in an extended conformation with non-covalent interactions between Ub and 
the HECT domain C-lobe, suggesting that HECT-type E3s may also promote open E2~Ub states 
[7]. However, the open E2~Ub state appears to be stabilized by interactions between Ub and the 
HECT active-site-containing C-lobe, while our NMR results show that the E2-binding domain 
(RING1) of RBR E3s actively disfavors E2~Ub closed states on its own. Likely, this feature is 
particularly important for RBR E3s like HHARI that can bind E2~Ub in their auto-inhibited 
15 
 
states where RING1 and RING2 are very far removed as it serves to inhibit premature Ub 
transfer from the bound E2~Ub before an activation event allows recruitment of RING2 to occur.  
Given the structural similarities between canonical RINGs and RBR RING1s, their opposite 
effects upon binding E2~Ub is surprising. As pointed out above, RING1 domains lack the basic 
linchpin residue responsible for stabilizing closed E2~Ub states, but this does not adequately 
explain why RING1 binding actively promotes open E2~Ubs. One possibility is that RING1 
binds Ub in the context of E2~Ub as has been suggested for Parkin[33], but our NMR data for 
HHARI and RNF144 RING1 binding to E2~Ub presented here do not indicate Ub binding by 
RING1. Instead, NMR binding experiments with either UbcH5 or UbcH7 identified an E2 
surface that includes residues of the cross-over-helix that are not perturbed by canonical RING 
binding, suggesting that RING1 binds to a shifted or expanded surface on the E2. Notably, this 
“new” E2 binding surface overlaps with that contacted by Ub in closed E2~Ub states, suggesting 
that RING1 binding may effectively compete with Ub binding, thereby disfavoring closed 
conformations. The details of HHARI RING1:E2~Ub must await further structural 
characterization. 
Our finding that mutation of Ub hydrophobic patch residues affects the first Ub transfer step for 
HHARI, Parkin, and HOIP led to our subsequent discovery of a Ub-binding surface on RING2. 
Although there are differences in severity among different Ub hydrophobic patch mutations for 
different RBR E3 ligases, all three E3s tested exhibit reduced activity with V70A-Ub and Q49E-
Ub. Consistent with the modest degree of sequence conservation in RBR RING2s, we speculate 
that the Ub binding surface on RING2 is composed of some different residues in each RBR E3 
(Fig 5A and Fig EV4B). That the composition of the Ub binding regions on RING2s varies is not 
particularly surprising. Various Ub binding domains that use the same Ub hydrophobic patch 
differ in primary and tertiary structure indicating that there are many possible binding modes 
between the Ub hydrophobic patch and a binding motif. We therefore propose that RING2 
binding to the hydrophobic patch of Ub serves to recruit RING2 to the RING1-bound E2~Ub 
and that this feature is shared among RBR E3 ligases.  
While this study was under review, a crystal structure of HOIPRBR-LDD bound to UbcH5~Ub was 
published that is consistent with the main tenets of the model presented here [48]. The structure 
reveals a myriad of interactions among the E3, E2, and Ub that involve multiple copies of HOIP, 
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UbcH5, and Ub in the asymmetric unit. Nevertheless, a number of features and interactions 
observed in the crystal are analogous to what we report here from solution measurements. First, 
the E2~Ub bound to RING1 of the HOIPRBR-LDD is in an open conformation. In the crystal this 
Ub moiety forms an extensive interface with the E3 including residues from the RING1-IBR 
linker and the IBR. Our work demonstrates that HHARI and RNF144 RING1 constructs (which 
include the RING1-IBR linker) are sufficient to induce open E2~Ub conformations, so the 
importance of additional contacts with the IBR during the first step of ubiquitin transfer remain 
to be addressed. Second, the hydrophobic patch of this Ub makes contacts to the IBR-RING2 
linker and RING2 of another HOIP molecule in the crystal and this interaction is centered around 
Ub residues I44 and V70, in agreement with our assays showing that I44A-Ub and V70A-Ub 
significantly impair Ub transfer with HOIPRBR-LDD. (Fig EV4B). As the HOIP/E2~Ub structure is 
of UbcH5~Ub which is already in open states when unbound to an E3, our study provides an 
important additional insight that cannot be inferred from the crystal structure: RING1 binding 
actively opposes closed states, rather than just failing to promote them. 
Structural and biochemical investigations have provided rationales for the effects of many patient 
mutations in Parkin, but the T415N mutation has remained enigmatic [49]. Substitution of 
Thr415 with Asn decreases ligase activity substantially though it alters neither the structure nor 
solubility of Parkin [43, 50, 51]. Thr415 is proposed to be involved in a hydrogen-bonding 
network around the active site that is required for catalysis [43]. In our study, we found that the 
analogous mutation in HHARI, T341N, also decreases ligase activity and, importantly, decreases 
Ub binding to HHARI RING2 (Fig 6D&E, Fig EV5B). Thus, our discovery of a Ub-binding site 
composed of residues from RING2 and its proximal linker provides another possible mechanistic 
explanation for the loss of function associated with this Parkin mutation. Our results support an 
earlier report that peptides spanning the Parkin IBR-RING2 linker bind Ub in a peptide array 
assay [40]. Thr415 is conserved in orthologs of Parkin as well as orthologs in HHARI. 
Altogether, the observations lead us to propose that the pathogenic Parkin T415N mutation 
disrupts Ub binding and consequently disables the recruitment of RING2 to the bound E2~Ub 
conjugate to enable the transfer of Ub onto the Parkin active site. It remains possible that the 
detrimental effect of T415N on Parkin activity is due to a combination of the loss of Ub binding 
to RING2 and the loss of a critical hydrogen-bonding network around the active site [43].  
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A common feature of RBR E3 ligases is that they exist in auto-inhibited states characterized by 
low activity [8, 10, 29-34, 40, 52]. Structures of HHARI and Parkin reveal two common features 
that define the auto-inhibited states [29-34]. First, the active site Cys on RING2 is at least 
partially buried by another domain. Second, the E2-binding RING1 domain and the RING2 
domain are separated by large distances (Fig 7A). Both features imply that RBR E3 ligases must 
undergo major rearrangements to become active enzymes. Details of release of auto-inhibition 
are specific for each RBR E3 and are not yet fully defined. [8, 10, 29-34, 40, 52]. However, they 
share one common feature: the E2-binding RING1 domain and the active-site-containing RING2 
domain must come together for transfer of Ub from the E2~Ub onto the E3 active site. In auto-
inhibited conformations of HHARI and Parkin, the domains of the RBR are connected by long 
flexible linkers that presumably allow the domains to adopt positions that are quite remote from 
one another. Other than a short helix referred to as the REP (repressor) element in Parkin, linkers 
between IBR and RING2 domains are either not observed or are unstructured in existing crystal 
structures of HHARI and Parkin [29-34, 52]. However, the linker proximal to HHARI RING2 is 
observed in solution by NMR and in crystal structures of HOIPRING2-LDD and HOIPRBR-LDD bound 
to E2~Ub where in all cases it forms a short helix (Fig EV5C and [41, 45, 48]). Importantly, 
several of the HHARI residues that we observed to be perturbed upon Ub binding are in the part 
of the IBR-RING2 linker that is seen to form a helix. We propose that the linker is extended 
and/or disordered in auto-inhibited states, resulting in an incomplete RING2 Ub-binding surface 
that will have little or no ability to bind Ub. Upon release of the inhibitory domain(s), the linker 
could undergo a coil-to-helix transition to complete the Ub-binding site on RING2, enabling it to 
be recruited to the conjugated Ub moiety bound at RING1. We propose that open E2~Ub 
conformations induced by RING1 binding expose the hydrophobic patch on the conjugated Ub 
to allow Ub within the RING1-bound E2~Ub to contact RING2 and ensure proper transfer of Ub 
onto the RING2 active. Although the structural details by which this mechanism is carried out 
may vary among RBRs, we believe that the main features defined here will be shared among 
them. 
In closing, we note that our original proposal that RBR E3s are RING-HECT hybrids remains 
true in a structural sense. But findings reported here show clearly that the RBRs have evolved 
their own distinctive mechanistic strategies to achieve their function. Most remarkably, the 
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centerpiece of the canonical RING allosteric mechanism for Ub transfer has been turned on its 
head by the RBRs. 
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Materials and Methods 
Cloning and constructs 
The following constructs were used in this study. If not stated otherwise the following constructs 
are human and full-length:  HHARI-RBR (aa 177-395), HHARI-RING2 (aa 325-396), HHARI-
RING2-∆L (aa 336-395), HHARI-RING1 (aa 177-270), GST-Parkin- RBR (aa 217-465, rat), 
TRIAD1-∆ARI (aa 1-348), RNF144 RING1 (aa 2-108), HOIP-RBR-LDD (aa 697-1072), HOIP-
RING2 (aa 853-1072), E4BU (aa 1142-1173, mouse), BRCA1/BARD1 (aa 1-100/26-140), 
UbcH7WT or UbcH7C86S, UbcH5cWT or  UbcH5cC85S , His6-Ubc13C87S, E4BU-HHARI-hybrid 
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(mouseE4BU aa1142-1173, HHARI aa 271-396) with either WT HHARI RING2 active site 
C357 or C357A. HHARI RING1 and E4BU-HHARI-hybrid were cloned into pGEX-4T in-frame 
with thrombin-cleavable, N-terminal GST-tag. RNF144 RING1 was cloned into a His6-Sumo 
vector (N-terminal tag). TRIAD1-∆ARI was cloned into pet28a in-frame with His6-T7 at the N-
terminus. 
Expression and purification of recombinant proteins 
Proteins were expressed either in LB or minimal M9 medium supplemented with [15N]-
ammonium chloride or 13C-glucose in Escherichia Coli (BL21 DE3 cells) and induced with 200 
μM IPTG at 16°C for 18-22 hours. Media for E3s (except E4BU) was supplemented with 0.2mM 
Zn2+. UbcH5c, UbcH7, His6-Ubc13, BRCA1/BARD1, E4BU, GST-HHARI-RBR, GST-Parkin-
RBR, HOIP-RBR-LDD, HOIP-RING2 were purified as previously described [6, 8, 35, 36, 41, 
53]. GST-E4BU-HHARI-hybrid was purified as GST-HHARI-RBR.HHARI RING1 and RING2 
constructs were purified using GST columns (GE Healthcare and Life Sciences) in 50mM TRIS, 
200mM NaCl, pH8.0 and eluted with 10mM Glutathione. GST-tags cleaved with thrombin 
(Sigma Aldrich) and removed by size-exclusion chromatography (25mM NaPO4, 150mM NaCl, 
pH7.0). His6-T7-TRIAD1-∆ARI and His6-Sumo-RNF144-RING1 were purified using Ni2+-
affinity chromatography. His6-Sumo-tag was removed from RNF144-RING1 using sumo 
protease in 50mM TRIS, 200mM NaCl, 1mM DTT, pH8.0. Finally, size-exclusion 
chromatography in 25mM NaPO4, 150mM NaCl, pH7.0 was performed on His6-T7-TRIAD1-
∆ARI and cleaved RNF144-RING1.  
E2~Ub discharge assays 
2 μM wheat E1, 20 μM UbcH7 or UbcH5, 10 μM of Ub or HA-Ub (WT or mutant), 5mM ATP 
were mixed at 37°C in 25 mM NaPO4, 150 mM NaCl, pH 7.0 for 20min. Charging reactions 
were quenched with the addition of  0.1 units of apyrase (Sigma Aldrich)/10 μl reaction for 
5min.  A zero minute time point was taken using non-reducing SDS-PAGE load dye prior to 
incubation with either free nucleophile and/or E3. Cys reactivity assays: Charging reactions were 
diluted twofold and incubated at 37°C with a final concentration of either 5 mM Cys in the 
absence or presence of 75 μM E3 (HHARI RING1). Reactions were quenched at given time 
points by addition of non-reducing SDS-PAGE load dye. Products were visualized with 
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Coomassie blue stain. Parkin discharge assays: Charging reactions were diluted twofold and 
incubated at 37°C with a final concentration of 4 μM GST-Parkin-RBR. Reactions were quenched 
at given time points by addition of non-reducing SDS-PAGE load dye. UbcH7~Ub discharge and 
E3-Ub product formation was visualized by western blotting for HA-Ub (HA antibody from Life 
Tein, LT0422). HOIP~Ub/HHARI~Ub capture assay: 50 μl charging reactions were quenched 
with addition of 5μl apyrase for 5min at room temperature (RT). Time point zero was taken 
immediately prior to addition of H887A-HOIPRBR-LDD or H359A-HHARIRBR to a final 
concentration of 5 μM E3. Reactions were performed at RT and quenched at given time points 
by addition of non-reducing SDS-PAGE load dye. Product formation was visualized by western 
blotting for HA-Ub and GST (HHARI).  
Ubiquitination assays 
For E3 auto-ubiquitination assays 0.5 μM wheat E1, 2 μM E2, 2 μM  E3 (GST-HHARIRBR, T7-
TRIAD1ΔARI, GST-Parkin-RBR, Flag-BRCA1/BARD1) and 20 μM  Ub were incubated at 
incubated at 37°C in 25 mM NaPO4, 150 mM NaCl, pH 7.0. Reactions were initiated with 10 
mM ATP and quenched with SDS-PAGE reducing buffer. Samples were run on SDS-PAGE gel 
and visualized on Western blots (blotting for tags on E3). Antibodies used: GST antibody - Life 
Tein, LT0423 (Fig 1, 4, 6); Flag antibody -Sigma Aldrich, F3165 (Fig 1); T7 antibody- EMD 
Millipore, 69522 (Fig 1). Free linear chain building assays using HOIPRBR-LDD were done as 
described previously [41]. 
Generation of stable E2-O-Ub 
10 μM human E1, 250 μM E2 (UbcH7C86S, UbcH5cC85S or His6-Ubc13C87S), 750 μM Ub, 12.5 
mM ATP where incubated at 37°C for 8 hours in 25 mM NaPO4, 150 mM NaCl, pH 7.0. 
Charged species were separated from uncharged species using size exclusion chromatography.  
NMR experiments 
The same buffer (25 mM NaPO4, 150 mM NaCl, pH7.0, 10% D2O) and temperature (298K) 
were used for all experiments. All (1H,15N)-HSQC-TROSY experiments were acquired at field 
strengths of 500 Mhz except for data collected for Fig 6A where 600 Mhz was used instead.  The 
following concentrations where used for each Figure. Fig 1: 220uM 15N-UbcH5-O-15N-Ub Fig 2:  
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250 μM of 15N-UbcH7C86S and 15N-UbcH7-O-UbI44A, 200 μM of 15N-UbcH7-O-Ub; Fig EV2: 
250 μM free 15N-UbcH7C86S and 250 μM 15N-UbcH7C86S + 125 μM HHARI RING1; Fig3A, left 
panel: 50 μM 15N-Ub, 200 μM free UbcH7-O-15N-Ub, 160 μM UbcH7-O-15N-Ub + 200 μM 
HHARI RING1; Fig 3C: 200 μM free UbcH7-O-15N-Ub, 160 μM UbcH7-O-15N-Ub + 200 μM 
HHARI RING1; 70 μM UbcH7-O-15N-Ub + 200 μM RNF144 RING1; 220 μM UbcH7-O-15N-
Ub + 220 μM BRCA1/BARD1; Appendix Fig S4: 160 μM UbcH7-O-15N-Ub + 510 μM E4BU; 
Fig EV3: 50uM 15N-Ub, 100uM UbcH13-O-15N-Ub, 100uM Ubc13-O-15N-Ub + 300uM HHARI 
RING1.Fig 6A: 100 μM free 15N-HHARI RING2(-ΔL), 100 μM 15N-HHARI RING2(-ΔL)+ 1 
mM Ub (either WT or V70A); Fig 6E: 50 μM free 15N-Ub, 50 μM 15N-Ub + 500 μM HHARI 
RING2 (WT or mutants).   
(1H,13C)-HSQC-TROSY experiments for Fig 3B & Appendix Fig S3 were acquired at 500 Mhz 
(200 μM free 13C-UbcH7 C86S, 200 μM 13C-UbcH7-O-Ub, 125 μM 13C-UbcH7-O-Ub + 150 μM 
HHARI RING1) or 600Mhz (300 μM 13C-UbcH7C86S + 360 μM HHARI RING1). 
NMRPipe/NMRDraw [54] was used to process NMR data. NMRViewJ (One Moon Scientific) 
was used for data visualization [55]. The equation Δδ = [(Δδ15N/5)2 + (Δδ 1H)2]1/2  was used 
to calculated chemical shift perturbations of 2D Trosy-HSQC NMR experiments.  
 
Figure Legends 
Figure 1. RBR E3 ligases do not require closed states of E2~Ub for ubiquitin transfer. a) 
Auto-ubiquitination assays in which the E3 acts as both an E3 and as proxy substrate were 
performed with GST-HHARIRBR, T7-Triad1ΔAri, GST-ParkinRBR, and Flag-BRCA1/BARD1 and 
either UbcH5WT or UbcH5L104Q as the E2. Products were visualized by western blotting against 
indicated tags on E3s. Times given are post-ATP addition. b) Overlay of (1H,15N)-HSQC-
TROSY spectra of 15N-UbcH5-O-15N-Ub in the absence (black) and presence (red) of 0.5mol 
equiv. HHARI RING1. A subset of UbcH5 peaks, but not Ub peaks, shift and broaden upon 
HHARI RING1 binding. c) CSPs from (b) are mapped onto the structures of UbcH5c (PDB 
2fuh) and Ub (PDB 1ubq). Residues that exhibit loss of intensity > 1 stdv upon RING1 binding 
(intensity < 0. 47) are colored on each structure: UbcH5 residues 5, 6, 7, 16, 20, 22, 56, 62, 74, 
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87, 90, 91, 96, 97, 99-103, 137, 138 (pink) and Ub residues 48, 50 (yellow). The lack of CSPs on 
the UbcH5 cross-over helix and on the surface of Ub signifies that HHARI RING1 does not 
induce closed UbcH5~Ub. d) CLUSTAL OMEGA alignments of the C-terminal sequences of 
RBR RING1 domains (top) and canonical RING domains (bottom). Each alignment includes the 
7th and 8th Zn2+ coordinating positions (gray). The allosteric linchpin position critical for E2~Ub 
activation by RING-type E3s is highlighted in yellow. RBR RING1 domains lack the allosteric 
linchpin.  
Figure 2. UbcH7~Ub populates E3-independent closed conformations. a) Histogram of CSPs 
between free 15N-UbcH7 and 15N-UbcH7-O-Ub identifies UbcH7 residues affected by 
conjugation to Ub. Active site (Ser86) is indicated with a star and cross-over helix residues (101-
113) are marked with a gray cylinder. INSET. CSPs greater than 1 stdv (> 0.115 ppm) are 
highlighted in yellow on a surface representation of UbcH7 (PDB 1fbv). The view on the left 
shows the surface that contains the UbcH7 cross-over helix. b) Region of 1H-15N-HSQC TROSY 
spectra containing resonances of the cross-over helix residues S107 and Q106 are overlaid: 
unconjugated 15N-UbcH7 (blue), 15N-UbcH7-O-Ub (black), and 15N-UbcH7-O-UbI44A (red). 
Peaks representing S107 and Q106 in the context of UbcH7~Ub-I44A (red) are closer to peaks 
observed in free UbcH7(blue) than UbcH7~Ub-WT (black) indicating that I44A of Ub disrupts 
interactions with the cross-over helix of UbcH7.  
Figure 3. HHARI RING1 disfavors closed E2~Ub conformations. a) Region of 1H-15N-HSQC 
TROSY spectra that contains Gln49 Ub resonance are overlaid: free 15N-Ub (blue), UbcH7-O-
15N-Ub (black), and HHARI RING1-bound UbcH7-O-15N-Ub (red). Black arrow highlights 
perturbation upon conjugation to UbcH7 (black arrow) and red arrow highlights perturbation of 
conjugated Ub upon HHARI RING1 binding to UbcH7. b) Region of 1H-13C-HSQC spectra of  
13C-UbcH7 (blue), 13C-UbcH7-O-Ub (black), and HHARI RING1-bound 13C-UbcH7-O-Ub (red) 
that includes the methyl (13CH3) resonance of the surface-exposed UbcH7 cross-over helix 
residue, Ala 110 (black arrow) is shown. The 13CH3 peak of Ala110 either broadens dramatically 
or shifts to an unknown position in the spectrum of 13C-UbcH7-O-Ub (black) and reappears at its 
position in free UbcH7 in the presence of HHARI RING1, consistent with disruption of closed 
UbcH7~Ub conformations. Pairwise overlays and larger spectra are provided in Appendix Fig 
S3. c) Regions of 1H-15N-HSQC-TROSY spectra of UbcH7-O-15N-Ub in the absence (black) and 
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presence (red) of a RING1 domain from the RBR E3s HHARI (left) or RNF144 (middle) or a 
canonical RING domain of BRCA1/BARD1 (right). The perturbations on Ub due to binding of 
HHARI RING1 and RNF144 RING1 are remarkably similar, while binding of the canonical 
RING domain of BRCA1/BARD1 has no observable effect on the Ub spectrum. Gray boxes 
mark area expanded in a) 
Figure 4. RING1 opening of E2~Ub enforces transfer via the RING2 active site. a) 
Schematic representation of the two constructs used. LEFT. GST-tagged HHARIRBR with its 
native RING1 domain that does not induce closed conformations of UbcH5~Ub. RIGHT. GST-
tagged HHARI construct in which the RING1 domain was replaced with the Ubox domain of 
E4BU to generate the UBR-hybrid that promotes closed conformations of UbcH5~Ub. b) LEFT. 
Auto-ubiquitination assays were performed with wild-type HHARIRBR or an active site-dead 
mutant (C357A- HHARIRBR). Products were visualized by western blotting against GST. The 
zero time point was taken immediately prior to ATP addition, all other times are post-ATP 
addition. RIGHT. Identical assays as shown on left were performed with the UBR-hybrid. The 
active site-dead mutant (C357A) retains substantial auto-ubiquitination activity signifying that 
UbcH5~Ub is able to transfer Ub directly onto the GST-UBR-hybrid construct, bypassing the 
RING2 active site Cys. 
Figure 5. The Ub hydrophobic patch plays a role in Ub transfer from E2~Ub onto RING2 
of RBR E3 ligases.  a) LEFT. E3 auto-ubiquitination assays were performed using various Ub 
mutants (I44A, R42A, Q49A, Q49E, and V70A) and the RBR E3s HHARIRBR (left) and 
ParkinRBR (right). Products were visualized by western blotting against HA-Ub. Samples were 
analyzed 30 minutes after ATP addition. b) The hydrophobic patch of Ub (PDB 1ubq) is colored 
yellow on a surface representation and positions of each mutation are noted. c) UbcH7~Ub 
conjugates were preformed with either with WT-Ub or I44A-Ub. After the addition of apyrase to 
quench the charging reaction, UbcH7~UbWT (left) or UbcH7~UbI44A (right) was incubated with 
ParkinRBR. The disappearance of each UbcH7~Ub species and appearance of auto-ubiquitinated 
E3 was visualized under non-reducing conditions by western blotting for HA-Ub. Time was 
recorded post addition of ParkinRBR. E2~Ub conjugated with I44A-Ub does not disappear over 
the timecourse of the reaction. d) UbcH7 conjugated with WT-Ub, I44A-Ub, or V70A Ub as 
indicated was incubated with either H887A-HOIPRBR-LDD (left) or H359A-HHARIRBR (right) 
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mutants that allow trapping of the E3~Ub thioester with WT-Ub (Stieglitz et al, 2013;[29]). 
While a HOIP~Ub thioester species is observed when UbcH7 was charged with WT-Ub, no 
detectable transfer occurs with the I44A-Ub conjugate (left). Similarly, V70A-Ub shows reduced 
formation of the HHARI~Ub thioester (right). In addition to blotting for HA-Ub, the blot on the 
right was also blotted for GST-HHARI.  
Figure 6. HHARI RING2 binds to Ub. a) Top panel. Regions of 1H-15N-HSQC TROSY 
spectra of 15N-HHARI RING2 in the absence (black) and presence of excess Ub (red). Middle 
panel. Identical spectral region, but in the presence of Ub-V70A (red). Bottom panel. Identical 
spectral region, but spectra are from a truncated HHARI RING2 construct that lacks N-terminal 
residues 325-335 (HHARI RING2-ΔL). b) Residues with CSPs greater than 1 stdv (HHARI 
residues 333, 337-342, 352-354, 363, 365, 371) are colored red in a cartoon (left) and surface 
(right) representation of HHARI RING2 (PDB 2m9y). The active site C357 is in shown in 
yellow. c) Sequence alignment of HHARI and Parkin RING2 domains. HHARI residues 
perturbed by Ub binding (panel a) are in red. Residues that decrease auto-ubiquitination activity 
when mutated in HHARIRBR are indicated with black boxes. d) Mutations in the Ub binding 
surface of RING2 decrease activity in E3 auto-ubiquitination assays. Time points (10min) are 
visualized by western blotting for the GST-tag on HHARI. Relative activity of HHARI WT and 
mutant forms is clearest when the intensity of the unmodified HHARI band is compared. e) 1H-
15N-HSQC TROSY spectra of 15N-Ub demonstrate binding by WT HHARI RING2, but not by 
mutant HHARI RING2 constructs that exhibit decreased auto-ubiquitination activity. Overlay of 
15N-Ub spectra in the absence (black) and presence of WT-HHARI RING2 (red), W336A-
HHARI RING2 (blue), T341N-HHARI RING2 (green), or E352A-HHARI RING2 (purple). 
HHARI mutations that exhibited reduced binding to Ub also show decreased ubiquitination 
activity in panel d).  
Figure 7. Model of RBR E3 Ub transfer mechanisms. a) Auto-inhibited HHARI structure is 
shown in cartoon representation (PDB 4KC9). The E2-binding site (green oval) on RING1 (pink) 
is separated from the active site Cys (yellow spheres) on RING2 (orange) by more than 40 Å. 
The IBR domain (dark blue) connects RING1 and RING2 and the Ariadne domain (grey) 
occludes the active site Cys. b) A model depicts the events required for Ub transfer by HHARI 
(with no intended order). E2~Ub binding to RING1 favors open E2~Ub conformations (middle 
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panel) that expose the Ub hydrophobic patch (orange circle). Movement of the Ariadne domain 
(middle panel) exposes the active site Cys (right panel, yellow star) and may allow a disorder-to-
helix transition of the IBR-RING2 linker (dotted black line in right panel, not seen in structure in 
A) which completes the Ub binding site on RING2 (yellow sphere, right panel). Open E2~Ub 
conformations make the hydrophobic patch of Ub (orange circle) available for recruitment by 
RING2 to ensure transfer of Ub to the active cite Cys.  
 
Expanded View Figure Legends 
Figure EV1. HOIP does not require closed states of E2~Ub for linear chain formation. 
Linear Ub chain building reactions were performed using HOIPRBR-LDD and either UbcH5WT or 
UbcH5L104Q. Product formation (free linear Ub chains) was visualized by Coomassie-blue 
staining.   
Figure EV2. NMR mapping of HHARI RING1 binding to UbcH7. a) Spectral overlay of 15N-
UbcH7 in the absence (black) and presence (red) of 0.5 mol equiv. HHARI RING1. Affected 
resonances show peak doubling, characteristic of a high-affinity complex, where a new set of 
resonances that correspond to resonances from the complex appear simultaneously with 
resonances of the unbound species. b) Histogram displays the ratio of peak intensity of UbcH7 
residues (bound/free) measured from the spectra shown above. The average intensity ratio is 
indicated with a grey dashed line. c) LEFT. Surface (top) and cartoon (bottom) representation of 
UbcH7 (pdb 1fbv). Residues that exhibit loss of intensity > 1 stdv from the average upon RING1 
binding (intensity < 0.448) are colored in pink (residues 6, 11, 13, 14, 28, 40, 57, 61, 64, 78, 87, 
89, 90, 96, 98-100, 102-106, 108). RIGHT. For comparison, UbcH5 residues that are perturbed 
(either CSP or intensity loss) upon RING1 binding are indicated in pink (CSPs: > 0.028ppm and 
intensity <0. 44)  
Figure EV3. HHARI RING1 disruption of (E3-independent) closed E2~Ub conformations. 
a) Similar to UbcH7, Ubc13~Ub populates closed states in the absence of an E3 [35]. Shown 
here are three 1H-15N-HSQC TROSY spectra of Ub overlaid: free 15N-Ub (blue), Ubc13-O-15N-
Ub (black), and Ubc13-O-15N-Ub in the presence of 3 mol equiv. HHARI RING1 (red). Due to 
the weak affinity binding of Ubc13 to HHARI RING1, the complex is far from saturation and the 
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spectrum exhibits fast-to-intermediate exchange behavior. Therefore, the observed CSPs for the 
effects of RING1 binding to Ubc13-O-15N-Ub are quite small (black versus red). Black arrows 
highlight several Ub resonances that shift along the same trajectory (but opposite direction) upon 
binding HHARI RING1 as experienced when Ub is conjugated to Ubc13, consistent with 
Ubc13~Ub populating more open-like states when in complex with HHARI RING1.  
Figure EV4. Ub hydrophobic patch involvement in linear chain building by the RBR E3 
HOIP. a) Timecourses of linear-chain-building assays using HOIPRBR-LDD and either UbcH5 
(left) or UbcH7 (right) conjugated with WT-Ub or I44A-Ub as followed by Coomassie-stained 
gels. The I44A mutation in the donor Ub does not impair the formation of di-Ub (Smit et al, 
2012), yet I44A-Ub significantly reduces linear chain building ability by HOIPRBR-LDD . b) 
UbcH7 was pre-conjugated with either WT- or mutant-Ub (as indicated) and the reaction was 
quenched with apyrase. Each UbcH7~Ub species was incubated with H887A-HOIPRBR-LDD  to 
enable detection of the E3~Ub intermediate (Stieglitz et al, 2013). Samples were analyzed on 
SDS-page under non-reducing conditions and subsequently visualized by western blotting for the 
HA-tag on Ub. Time was recorded post addition of H887A-HOIPRBR-LDD. Note: The HA-
antibody cross-reacts with free HOIP (see *).  
Figure EV5.  Comparison of RBR RING2 domains. a) RING2 sequence alignments were 
generated using CLUSTAL OMEGA. Residues observed to be perturbed upon Ub binding to 
HHARI RING2 in NMR titration experiments are highlighted in red. HHARI residues that were 
mutated and tested for change in activity are marked with a (ǂ) with red indicating decreased and 
black indicating no observable change in activity (see Fig 6C). Green bars highlight residues that 
are important for Ub binding of HHARI RING2 that are well conserved among RBR RING2s. 
The active site Cys is marked with a yellow bar. 7th and 8th Zn2+coordinating residues are not 
shown. b) Structural overlay of NMR solution structures of Parkin (teal, PDB 2lwr) and HHARI 
(orange, PDB 2m9y) RING2 domains. RING2 residues perturbed upon Ub binding (Fig 6A) are 
colored dark red on HHARI RING2. The HHARI RING2 mutations T341N abrogates Ub 
binding and decreases ligase activity (Fig 6D&E). INSET. The analogous mutation in Parkin, 
T415N, has been linked to early-onset Parkinson’s disease (Abbas et al, 1999). c) Structural 
overlay of three RING2 domains: a HHARI NMR solution structure (orange, PDB 2m9y), a 
HHARI crystal structure (yellow, PDB 4kc9) and a HOIP crystal structure (grey, PDB 4ljq). An 
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enlargement of the N-terminal region that is part of the IBR-RING2 linker shows a helical 
disposition of the linker in the HOIP and HHARI NMR, but not in the HHARI crystal structure.  
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